论文部分内容阅读
目的观察复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法选择医院收治的慢性乙型肝炎肝纤维化患者90例作为研究对象,随机分为观察组和对照组,每组各45例。对照组采用恩替卡韦治疗,观察组在对照组治疗基础上加用复方鳖甲软肝片治疗,比较2组治疗前后肝功能指标、肝纤维化情况及彩色多普勒超声仪检测治疗前后门静脉主干内径和脾脏厚度。结果 2组治疗后肝功能指标、肝纤维化指标及B型超声指标较治疗前均明显改善,差异有统计学意义(P<0.05);且观察组治疗后白蛋白(ALB)值高于对照组,其他各项指标低于对照组,差异均有统计学意义(P<0.05)。结论复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化有助于延缓肝纤维化进程,改善肝功能,疗效显著,值得在临床上推广应用。
Objective To observe the clinical efficacy of Fufang Biejia Ruangan Pian combined with entecavir in the treatment of chronic hepatitis B liver fibrosis. Methods Totally 90 patients with chronic hepatitis B liver fibrosis admitted to the hospital were selected as study subjects and randomly divided into observation group and control group with 45 cases in each group. The control group was treated with entecavir. The observation group was treated with Fufang Biejia Ruangan Tablet on the basis of the control group. The liver function indexes, liver fibrosis and color Doppler ultrasound before and after treatment were compared between two groups before and after treatment And spleen thickness. Results The liver function index, liver fibrosis index and B ultrasonic index of two groups after treatment were significantly improved compared with those before treatment (P <0.05), and the albumin (ALB) value of the observation group after treatment was higher than that of the control Group, other indicators lower than the control group, the difference was statistically significant (P <0.05). Conclusion Fufang Biejia Ruangan Pian combined with entecavir in the treatment of chronic hepatitis B liver fibrosis can delay the process of liver fibrosis and improve liver function, with significant curative effect, which is worth popularizing in clinic.